Home > > > South Korea Genetic Testing Market Analysis: Cancer Testing, Faster Results & Forecast to 2033

South Korea Genetic Testing Market Analysis: Cancer Testing, Faster Results & Forecast to 2033

Author : Johns Mark | Published On : 29 Apr 2026

South Korea Genetic Testing Market Overview

Market Size in 2024: USD 370.50 Million

Market Forecast in 2033: USD 1,052.95 Million

Market Growth Rate 2025-2033: 11.01%

According to IMARC Group's latest research publication, "South Korea Genetic Testing Market Report by Type (Predictive and Presymptomatic Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, and Others), Technology (Cytogenetic Testing and Chromosome Analysis, Biochemical Testing, Molecular Testing), Application (Cancer Diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, and Others), and Region 2025-2033", the South Korea genetic testing market size reached USD 370.50 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,052.95 Million by 2033, exhibiting a growth rate (CAGR) of 11.01% during 2025-2033.

How AI is Reshaping the Future of South Korea Genetic Testing Market

  • AI-powered diagnostic systems are enabling South Korean genomics companies to analyze millions of genetic variations with high accuracy, dramatically reducing the time required to diagnose rare and complex diseases.

  • Machine learning algorithms integrated into next-generation sequencing platforms are lowering sequencing costs and improving interpretation speed, making genetic testing more accessible to a broader patient population across South Korea.

  • Companies like 3billion are deploying AI tools in collaboration with pharmaceutical partners to detect conditions such as atypical Hemolytic Uremic Syndrome, transforming what was once a lengthy diagnostic process into a faster, data-driven workflow.

  • Government-backed precision medicine strategies are incentivizing AI adoption in clinical genomics, with hospitals integrating AI-assisted genetic analysis into oncology and cardiovascular care pathways.

  • AI-enabled mobile dashboards offered by direct-to-consumer testing providers are improving user experience by delivering faster results, personalized wellness insights, and actionable pharmacogenetic and nutrition-linked data directly to consumers.


 

Download a sample PDF of this report:  https://www.imarcgroup.com/south-korea-genetic-testing-market/requestsample

South Korea Genetic Testing Market Trends and Drivers:

The south korea genetic testing market is experiencing strong growth momentum driven by robust government funding and the country's ambitious national precision medicine agenda. The Ministry of Health and Welfare reported in February 2025 that over one million individuals had accessed government-sponsored genetic panels through public clinics, reflecting how deeply genetic services are being embedded into routine healthcare delivery. These panels assess traits related to medication response, nutrient metabolism, and carrier risk for hereditary conditions, enabling physicians to integrate genetic insights into personalized care plans. Reduced processing times and clearer, actionable reports are further strengthening public confidence in genetic testing as a standard component of preventive medicine.

Clinical integration is another powerful engine behind market growth, particularly in oncology. The National Health Insurance Service reported in May 2025 a dramatic increase in genetic test utilization within clinical practice, with hospitals routinely deploying multi-gene panels to tailor cancer therapies based on patients' individual genomic profiles. Expanded insurance coverage of these tests has broadened access significantly, reducing financial barriers that previously limited adoption to high-income patients or specialized research centers. Improved ethical frameworks and data-sharing protocols have also streamlined how clinical laboratories manage and act on genetic results, leading to more precise treatment decisions and improved patient outcomes across cancer, cardiovascular, and rare disease segments.

The rapid rise of direct-to-consumer genetic testing is further reshaping the market landscape. As reported by The Korea Times in July 2025, households across South Korea are increasingly ordering at-home test kits focused on ancestry, dietary predispositions, wellness traits, and pharmacogenetics. Early survey data shows that a meaningful share of users are modifying their fitness and dietary behaviors in response to test results, underscoring the real-world behavioral impact of consumer-facing genetic services. Service providers are responding by expanding their test panels and offering tiered product models that include nutrition-linked and medication-response modules, delivered through user-friendly digital platforms that eliminate the need for clinical gatekeeping and make genetic insights accessible to younger, tech-savvy demographics.


South Korea Genetic Testing Industry Segmentation:

The report has segmented the market into the following categories:

Breakup by Type:

  • Predictive and Presymptomatic Testing

  • Carrier Testing

  • Prenatal and Newborn Testing

  • Diagnostic Testing

  • Pharmacogenomic Testing

  • Others

Breakup by Technology:

  • Cytogenetic Testing and Chromosome Analysis

  • Biochemical Testing

  • Molecular Testing (DNA Sequencing and Others)

Breakup by Application:

  • Cancer Diagnosis

  • Genetic Disease Diagnosis

  • Cardiovascular Disease Diagnosis

  • Others

Regional Analysis:

  • Seoul Capital Area

  • Yeongnam (Southeastern Region)

  • Honam (Southwestern Region)

  • Hoseo (Central Region)

  • Others

Competitive Landscape:

  • 3billion

  • GC Genome

  • AstraZeneca Korea

  • Macrogen

  • DNA Link

  • Theragen Bio


Recent News and Developments in South Korea Genetic Testing Market

  • February 2025: South Korean genetic analysis company 3billion partnered with AstraZeneca Korea to develop an AI-powered diagnostic system targeting atypical Hemolytic Uremic Syndrome, capable of analyzing millions of genetic variations with high accuracy to significantly shorten the diagnostic process for patients in South Korea.

  • December 2024: GC Genome, a South Korean clinical genomics company providing prenatal and cancer diagnostic services to numerous hospitals and clinics, applied for a preliminary KOSDAQ listing review after receiving a high technology evaluation rating, with plans to strengthen its presence in North America following the anticipated IPO.

  • May 2025: The National Health Insurance Service expanded insurance coverage for genetic testing in clinical oncology and precision medicine settings, reducing patient costs and accelerating adoption of genomic panels across hospitals at the earliest stages of care.


Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

 

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.